Bank Of New York Mellon Corp Nuvalent, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $1.32 Million - $2.6 Million	71,590 New	71,590 $2.13 Million
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $119,389 - $175,515	8,811 Added 20.32%	52,182 $1.01 Million
Q2 2022 Aug 15, 2022	SELL	$7.4 - $15.07 $16,909 - $34,434	-2,285 Reduced 5.0%	43,371 $589,000
Q1 2022 May 11, 2022	BUY	$11.65 - $19.57 $194,857 - $327,327	16,726 Added 57.82%	45,656 $634,000
Q4 2021 Feb 11, 2022	BUY	$18.01 - $30.1 $67,033 - $112,032	3,722 Added 14.77%	28,930 $551,000
Q3 2021 Nov 12, 2021	BUY	$18.25 - $38.35 $460,046 - $966,726	25,208 New	25,208 $568,000

213

60.9M

311K

175K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.42B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.